CoChat

The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species

Open access
Nysten, Jana, Peetermans, Arne, Vaneynde, Dries, Demuyser, Liesbeth, Van Dijck, Patrick · 2024 · mBio

Preprint — published as 10.1128/mbio.02502-24

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

In recent decades, there has been an increase in the occurrence of fungal infections, yet the arsenal of drugs available to fight invasive infections remains very limited. The development of new antifungal agents is hindered by the restricted number of molecular targets that can be exploited, given the shared eukaryotic nature of fungi and their hosts which often leads to host toxicity. In this paper, we examine the riboflavin biosynthetic pathway as a potential novel drug target. Riboflavin is an essential nutrient for all living organisms. Its biosynthetic pathway does not exist in humans, who obtain riboflavin through their diet. Our findings demonstrate that all enzymes in the pathway are essential for Candida albicans , Candida glabrata, and Saccharomyces cerevisiae. Among these enzymes, Rib1 and Rib3 are the most promising targets. Auxotrophic strains, which mimic a drug targeting the biosynthesis pathway, experience rapid mortality in the absence of supplemented riboflavin. Nevertheless, the cells can still take up external riboflavin when supplemented. We identified Orf19.4337 as the riboflavin importer in C. albicans and named it Rut1. We found that Rut1 only facilitates growth at external riboflavin concentrations that exceed the physiological concentrations in the human body, making it unlikely that riboflavin uptake to act as a potential resistance mechanism for a drug targeting the biosynthesis pathway. Interestingly, the uptake system in S. cerevisiae is more effective than in C. albicans and C. glabrata, enabling an auxotrophic S. cerevisiae strain to outcompete an auxotrophic C. albicans strain in lower riboflavin concentrations. Importance: Candida species are a common cause of invasive fungal infections. Candida albicans, in particular, poses a significant threat to immunocompromised individuals. This opportunistic pathogen typically lives as a commensal on mucosal surfaces of healthy individuals, but it can also cause invasive infections associated with high morbidity and mortality. Currently, there are only three major classes of antifungal drugs available to treat these infections. Additionally, the efficacy of these antifungal agents is restricted by host toxicity, suboptimal pharmacokinetics, a narrow spectrum of activity, intrinsic resistance of fungal species, such as Candida glabrata , to certain drugs, and the acquisition of resistance over time. Therefore, it is crucial to identify new antifungal drug targets with novel modes of action to add to the limited armamentarium.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2024.03.01.582991

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 The riboflavin biosynthetic pathway. Riboflavin is synthesized from GTP and ribulose-5-phosphate, two derivatives of the purine pathway and the pentose phosphate pathway, respectively. Rib1, Rib2, and Rib7 convert GTP into 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione 5′-phosphate which is then dephosphorylated by a yet unknown enzyme. Ribulose-5-phosphate is converted by Rib3 and Rib4 to 6,7-dimethyl-8-ribityllumazine. Finally, Rib5 converts these two intermediates into riboflavin. Riboflavin can be converted into FMN or FAD by Fmn1 and/or Fad1 (28, 29).
Fig 1 The riboflavin biosynthetic pathway. Riboflavin is synthesized from GTP and ribulose-5-phosphate, two derivatives of the purine pathway and the pentose phosphate pathway, respectively. Rib1, Rib2, and Rib7 convert GTP into 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione 5′-phosphate which is then dephosphorylated by a yet unknown enzyme. Ribulose-5-phosphate is converted by Rib3 and Rib4 to 6,7-dimethyl-8-ribityllumazine. Finally, Rib5 converts these two intermediates into riboflavin. Riboflavin can be converted into FMN or FAD by Fmn1 and/or Fad1 (28, 29).CC BY · PubMed Central
Fig 2 The crucial role of riboflavin biosynthetic enzymes in C. albicans. (A) Homozygous deletion strains of all enzymes in the riboflavin biosynthetic pathway were cultured in a growth medium without supplemented riboflavin, and their absorbance was measured over time. (B) Growth of strains in a medium supplemented with 200 mg/L of riboflavin. (C) Growth of strains in a growth medium without external riboflavin supplementation and riboflavin production measured by fluorescent measurements. (D) Intracellular riboflavin levels were measured by fluorescent measurements in a flow cytometer where 10,000 cells were monitored per biological repeat. (E) Growth of the RIB1 deletion strain was monitored in a LoFlo medium with varying concentrations of riboflavin supplementation. (F) Growth of a RIB1 deletion strain in the absence of supplemented riboflavin in both LoFlo and in blood-simulative RPMI medium that contains a physiological riboflavin concentration of 0.2 mg/L. To assess cell survival, colony-forming units (CFUs) were counted every 24 hours on a YPD medium with 200 mg/L riboflavin to facilitate the growth of the surviving auxotrophic strains. (G) Fungal burden in the kidneys was assessed three and six days post-infection. Mice were intravenously challenged with 8.5 × 105 C. albicans cells. (H) Fungal burden in the brain. (I) Weight of the mice throughout the experiment. All in vitro experiments were conducted with three biological replicates, and the mean ± standard deviations (s.d.) are presented. Statistical analysis of in vitro experiments was performed by ordinary one-way ANOVA with Dunnett’s multiple comparisons test ****P < 0.0001. Statistical analysis of in vivo experiments was performed by two-way ANOVA with Bonferroni’s multiple comparisons test. ***P < 0.001; ****P < 0.0001.
Fig 2 The crucial role of riboflavin biosynthetic enzymes in C. albicans. (A) Homozygous deletion strains of all enzymes in the riboflavin biosynthetic pathway were cultured in a growth medium without supplemented riboflavin, and their absorbance was measured over time. (B) Growth of strains in a medium supplemented with 200 mg/L of riboflavin. (C) Growth of strains in a growth medium without external riboflavin supplementation and riboflavin production measured by fluorescent measurements. (D) Intracellular riboflavin levels were measured by fluorescent measurements in a flow cytometer where 10,000 cells were monitored per biological repeat. (E) Growth of the RIB1 deletion strain was monitored in a LoFlo medium with varying concentrations of riboflavin supplementation. (F) Growth of a RIB1 deletion strain in the absence of supplemented riboflavin in both LoFlo and in blood-simulative RPMI medium that contains a physiological riboflavin concentration of 0.2 mg/L. To assess cell survival, colony-forming units (CFUs) were counted every 24 hours on a YPD medium with 200 mg/L riboflavin to facilitate the growth of the surviving auxotrophic strains. (G) Fungal burden in the kidneys was assessed three and six days post-infection. Mice were intravenously challenged with 8.5 × 105 C. albicans cells. (H) Fungal burden in the brain. (I) Weight of the mice throughout the experiment. All in vitro experiments were conducted with three biological replicates, and the mean ± standard deviations (s.d.) are presented. Statistical analysis of in vitro experiments was performed by ordinary one-way ANOVA with Dunnett’s multiple comparisons test ****P < 0.0001. Statistical analysis of in vivo experiments was performed by two-way ANOVA with Bonferroni’s multiple comparisons test. ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Fig 3 Rib1 and Rib3 could be attractive drug targets in the riboflavin biosynthetic pathway. (A) The cultivation of heterozygous RIB strains on LoFlo medium. Growth was monitored by measuring the absorbance at 600 nm. (B) The riboflavin content was measured spectrophotometrically. (C) Intracellular riboflavin levels were measured by fluorescent measurements in a flow cytometer where 10,000 cells were monitored per biological repeat. Statistical analysis was performed by ordinary one-way ANOVA with Dunnett’s multiple comparisons test *P < 0.05; **P < 0.01; ****P < 0.0001. Each experiment was performed with three biological repeats and the mean ± s.d. is displayed.
Fig 3 Rib1 and Rib3 could be attractive drug targets in the riboflavin biosynthetic pathway. (A) The cultivation of heterozygous RIB strains on LoFlo medium. Growth was monitored by measuring the absorbance at 600 nm. (B) The riboflavin content was measured spectrophotometrically. (C) Intracellular riboflavin levels were measured by fluorescent measurements in a flow cytometer where 10,000 cells were monitored per biological repeat. Statistical analysis was performed by ordinary one-way ANOVA with Dunnett’s multiple comparisons test *P < 0.05; **P < 0.01; ****P < 0.0001. Each experiment was performed with three biological repeats and the mean ± s.d. is displayed.CC BY · PubMed Central
Fig 4 Rut1 is a major riboflavin transporter. Panels A, B, and C show the growth of wild-type strain SC5314, rib1△/△, rib1△/△ orf19.6263△/△ orf19.5720△/△ orf19.2751△/△ orf19.1584△/△, and rib1△/△ orf19.6263△/△ orf19.5720△/△ orf19.2751△/△ orf19.1584△/△ rut1△/△ in 50 mg/L, 100 mg/L and 200 mg/L of supplemented riboflavin, respectively. (D) The relative expression level of RUT1 in 0, 20, 50, 100, and 200 mg/L of supplemented riboflavin in the wild-type strain compared to the auxotrophic rib1△/△ strain. There are no data for the rib1△/△ strain as this condition is not viable. Statistical analysis was performed using two-way ANOVA with Bonferroni’s multiple comparisons tests. **P < 0.01. (E) The relative gene expression level of ORF19.1584, ORF19.2751, ORF19.6263, and ORF19.5720 in the auxotrophic rib1△/△ and rib1△/△ rut1△/△ strains when grown in LoFlo medium supplemented with 100 mg/L riboflavin. (F) The relative gene expression level of ORF19.1584, ORF19.2751, ORF19.6263, ORF19.5720, and RUT1 in the wild-type strain and the heterozygous RIB1/rib1△ strain that produces reduced amounts of riboflavin. The strains were grown in LoFlo medium. (G) Riboflavin uptake in the wild-type, auxotrophic rib1△/△, and rib1△/△ rut1△/△ strains is shown in pmol/(mg dry weight) and plotted against time. (H) Area under the curve (AUC) of three independent uptake experiments with three biological and at least two technical replicates. (I) The wild-type strain and six strains with a possible riboflavin export gene deletion were grown for 24 hours, and the fluorescence of the sterile supernatant was measured at 530 nm after excitation at 450 nm. Statistical analysis was performed by ordinary one-way ANOVA with Dunnett’s multiple comparisons test **P < 0.01. All figures show the mean ± s.d. of three biological replicates, except for panel G, which shows the mean of three technical repeats. The biological replicates for the latter panel were performed on different days and are included in Fig. S5. We observed day-to-day variance in our radioactivity experiments as expected, but all experiments show the same trend. All gene expression data show the mean ± s.d. of three biological repeats and each biological replicate represents the mean of three technical repeats.
Fig 4 Rut1 is a major riboflavin transporter. Panels A, B, and C show the growth of wild-type strain SC5314, rib1△/△, rib1△/△ orf19.6263△/△ orf19.5720△/△ orf19.2751△/△ orf19.1584△/△, and rib1△/△ orf19.6263△/△ orf19.5720△/△ orf19.2751△/△ orf19.1584△/△ rut1△/△ in 50 mg/L, 100 mg/L and 200 mg/L of supplemented riboflavin, respectively. (D) The relative expression level of RUT1 in 0, 20, 50, 100, and 200 mg/L of supplemented riboflavin in the wild-type strain compared to the auxotrophic rib1△/△ strain. There are no data for the rib1△/△ strain as this condition is not viable. Statistical analysis was performed using two-way ANOVA with Bonferroni’s multiple comparisons tests. **P < 0.01. (E) The relative gene expression level of ORF19.1584, ORF19.2751, ORF19.6263, and ORF19.5720 in the auxotrophic rib1△/△ and rib1△/△ rut1△/△ strains when grown in LoFlo medium supplemented with 100 mg/L riboflavin. (F) The relative gene expression level of ORF19.1584, ORF19.2751, ORF19.6263, ORF19.5720, and RUT1 in the wild-type strain and the heterozygous RIB1/rib1△ strain that produces reduced amounts of riboflavin. The strains were grown in LoFlo medium. (G) Riboflavin uptake in the wild-type, auxotrophic rib1△/△, and rib1△/△ rut1△/△ strains is shown in pmol/(mg dry weight) and plotted against time. (H) Area under the curve (AUC) of three independent uptake experiments with three biological and at least two technical replicates. (I) The wild-type strain and six strains with a possible riboflavin export gene deletion were grown for 24 hours, and the fluorescence of the sterile supernatant was measured at 530 nm after excitation at 450 nm. Statistical analysis was performed by ordinary one-way ANOVA with Dunnett’s multiple comparisons test **P < 0.01. All figures show the mean ± s.d. of three biological replicates, except for panel G, which shows the mean of three technical repeats. The biological replicates for the latter panel were performed on different days and are included in Fig. S5. We observed day-to-day variance in our radioactivity experiments as expected, but all experiments show the same trend. All gene expression data show the mean ± s.d. of three biological repeats and each biological replicate represents the mean of three technical repeats.CC BY · PubMed Central
Fig 5 The transporters do not have a direct impact on growth. (A) The growth of different strains in LoFlo without riboflavin (B) The relative expression level of RIB1 in the wild-type strain that was grown on different concentrations of riboflavin: 0, 20, 50, 100, and 200 mg/L. The bars show the mean ± s.d. of three biological replicates and three technical repeats. Statistical analysis was performed with an ordinary one-way ANOVA with Dunnett’s multiple comparisons test and the relative gene expression of RIB1 is not significantly different in higher riboflavin concentration versus no riboflavin.
Fig 5 The transporters do not have a direct impact on growth. (A) The growth of different strains in LoFlo without riboflavin (B) The relative expression level of RIB1 in the wild-type strain that was grown on different concentrations of riboflavin: 0, 20, 50, 100, and 200 mg/L. The bars show the mean ± s.d. of three biological replicates and three technical repeats. Statistical analysis was performed with an ordinary one-way ANOVA with Dunnett’s multiple comparisons test and the relative gene expression of RIB1 is not significantly different in higher riboflavin concentration versus no riboflavin.CC BY · PubMed Central
Fig 6 Characterization of the riboflavin biosynthetic pathway in Candida glabrata. (A) Deletion strains of all enzymes in the riboflavin biosynthetic pathway were cultured in a growth medium without supplemented riboflavin, and their absorbance was measured over time. (B) The strains were grown in a medium supplemented with 200 mg/L of external riboflavin (C) The strains were grown for 24 hours in a growth medium without external riboflavin supplemented and the riboflavin production was monitored over time by fluorescent measurements as described in the material and methods section. (D) A RIB1 deletion strain is grown in a blood-simulative RPMI medium that contains a physiological riboflavin concentration of 0.2 mg/L. CFUs were counted every 24 hours on a YPD medium with 200 mg/L riboflavin to assess cell survival. (E) The growth of the RIB1 deletion strain was monitored in a LoFlo medium with different concentrations of added riboflavin. (F) Survival curve of mice challenged with 5 * 107 C. glabrata cells injected via the lateral tail vein. The mice were immunosuppressed with 150 mg/kg of cyclophosphamide on days −3, 0, and 7. (G) The fungal burden of the kidneys was assessed two and three post-infection. An additional time point at 12 days post-infection was taken for the RIB1 deletion strain as they survived the whole experiment. (H) Fungal burden in the brain. All in vitro experiments were conducted with three biological replicates, and the mean ± s.d. is presented. Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparisons test to compare the different groups. One-way ANOVA with Bonferroni’s multiple comparisons test was performed to compare CFU’s in the RIB1 deletion strain group over time and this comparison is indicated with the blue lines. **P < 0.01; ***P < 0.001; ****P < 0.0001.
Fig 6 Characterization of the riboflavin biosynthetic pathway in Candida glabrata. (A) Deletion strains of all enzymes in the riboflavin biosynthetic pathway were cultured in a growth medium without supplemented riboflavin, and their absorbance was measured over time. (B) The strains were grown in a medium supplemented with 200 mg/L of external riboflavin (C) The strains were grown for 24 hours in a growth medium without external riboflavin supplemented and the riboflavin production was monitored over time by fluorescent measurements as described in the material and methods section. (D) A RIB1 deletion strain is grown in a blood-simulative RPMI medium that contains a physiological riboflavin concentration of 0.2 mg/L. CFUs were counted every 24 hours on a YPD medium with 200 mg/L riboflavin to assess cell survival. (E) The growth of the RIB1 deletion strain was monitored in a LoFlo medium with different concentrations of added riboflavin. (F) Survival curve of mice challenged with 5 * 107 C. glabrata cells injected via the lateral tail vein. The mice were immunosuppressed with 150 mg/kg of cyclophosphamide on days −3, 0, and 7. (G) The fungal burden of the kidneys was assessed two and three post-infection. An additional time point at 12 days post-infection was taken for the RIB1 deletion strain as they survived the whole experiment. (H) Fungal burden in the brain. All in vitro experiments were conducted with three biological replicates, and the mean ± s.d. is presented. Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparisons test to compare the different groups. One-way ANOVA with Bonferroni’s multiple comparisons test was performed to compare CFU’s in the RIB1 deletion strain group over time and this comparison is indicated with the blue lines. **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Fig 7 S. cerevisiae needs lower concentrations of riboflavin to sustain growth compared to the Candida species. (A) Homozygous deletion strains of all enzymes in the riboflavin biosynthetic pathway were cultured in a growth medium without supplemented riboflavin, and their absorbance was measured over time. (B) The strains were grown in a medium supplemented with 200 mg/L of riboflavin (C) The strains were grown for 24 hours in a growth medium without external riboflavin supplemented and the riboflavin production was monitored over time by fluorescent measurements. (D) A RIB1 deletion strain was grown in LoFlo and RPMI. CFUs were counted every 24 hours on a YPD medium with 200 mg/L riboflavin to assess cell survival. (E) The growth of the RIB1 deletion strain was monitored in a LoFlo medium with different concentrations of added riboflavin. All experiments were conducted with three biological replicates, and the mean ± s.d. is presented.
Fig 7 S. cerevisiae needs lower concentrations of riboflavin to sustain growth compared to the Candida species. (A) Homozygous deletion strains of all enzymes in the riboflavin biosynthetic pathway were cultured in a growth medium without supplemented riboflavin, and their absorbance was measured over time. (B) The strains were grown in a medium supplemented with 200 mg/L of riboflavin (C) The strains were grown for 24 hours in a growth medium without external riboflavin supplemented and the riboflavin production was monitored over time by fluorescent measurements. (D) A RIB1 deletion strain was grown in LoFlo and RPMI. CFUs were counted every 24 hours on a YPD medium with 200 mg/L riboflavin to assess cell survival. (E) The growth of the RIB1 deletion strain was monitored in a LoFlo medium with different concentrations of added riboflavin. All experiments were conducted with three biological replicates, and the mean ± s.d. is presented.CC BY · PubMed Central
Fig 8 ScMCH5 aids in riboflavin uptake in S. cerevisiae. (A) The growth of the Scrib1∆ mutant was assessed in different concentrations of supplemented riboflavin. (B) The growth of Scrib1∆ mch5∆ in different riboflavin concentrations. All experiments were conducted with three biological replicates, and the mean ± s.d. is presented.
Fig 8 ScMCH5 aids in riboflavin uptake in S. cerevisiae. (A) The growth of the Scrib1∆ mutant was assessed in different concentrations of supplemented riboflavin. (B) The growth of Scrib1∆ mch5∆ in different riboflavin concentrations. All experiments were conducted with three biological replicates, and the mean ± s.d. is presented.CC BY · PubMed Central
Fig 9 Auxotrophic Scrib1∆ outgrows auxotrophic Carib1∆/∆ in low riboflavin concentrations. (A) Auxotrophic RIB1 deletion strains of C. albicans and S. cerevisiae were grown together at equal starting OD600 in 5 mg/L of riboflavin and plated out on differentiating CHROMagar at different time points. The CFUs were counted after two days of incubation for both species and log-transformed. (B) Same setup as panel A with auxotrophic RIB1 deletion strains but in the presence of 200 mg/L riboflavin. (C) Wild-type strains of C. albicans and S. cerevisiae were grown together at equal starting OD600 in 5 mg/L of riboflavin and plated out on differentiating CHROMagar at different time points. The CFUs were counted after 2 days of incubation for both species and log-transformed. (D) The same setup as panel C but in the presence of 200 mg/L of riboflavin.
Fig 9 Auxotrophic Scrib1∆ outgrows auxotrophic Carib1∆/∆ in low riboflavin concentrations. (A) Auxotrophic RIB1 deletion strains of C. albicans and S. cerevisiae were grown together at equal starting OD600 in 5 mg/L of riboflavin and plated out on differentiating CHROMagar at different time points. The CFUs were counted after two days of incubation for both species and log-transformed. (B) Same setup as panel A with auxotrophic RIB1 deletion strains but in the presence of 200 mg/L riboflavin. (C) Wild-type strains of C. albicans and S. cerevisiae were grown together at equal starting OD600 in 5 mg/L of riboflavin and plated out on differentiating CHROMagar at different time points. The CFUs were counted after 2 days of incubation for both species and log-transformed. (D) The same setup as panel C but in the presence of 200 mg/L of riboflavin.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 53

  1. 10.1126/scitranslmed.3004404 · DOI · Paper page
  2. Clark C , Drummond RA . 2019. The Hidden Cost of Modern Medical Interventions: How Medical Advances Have Shaped the Prevalence of Human Fungal Disease. Pathogens 8. · DOI · Paper page
  3. 2020, Fungal infections in humans: the silent crisis, Microb Cell, 7, 143, 10.15698/mic2020.06.718 · DOI · Paper page
  4. 10.1016/S1473-3099(23)00692-8 · DOI · Paper page
  5. 10.1128/CMR.00029-06 · DOI · Paper page
  6. 10.1038/nrmicro.2016.157 · DOI · Paper page
  7. 10.1146/annurev-micro-091014-104330 · DOI · Paper page
  8. 10.1155/2014/615958 · DOI · Paper page
  9. Carolus H , Pierson S , Munoz JF , Subotic A , Cruz RB , Cuomo CA , Van Dijck P. 2021. Genome-Wide Analysis of Experimentally Evolved Candida auris Reveals Multiple Novel Mechanisms of Multidrug Resistance. mBio 12. · DOI · Paper page
  10. 10.1093/femsyr/fov025 · DOI
  11. Robbins N , Wright GD , Cowen LE . 2016. Antifungal Drugs: The Current Armamentarium and Development of New Agents. Microbiol Spectr 4. · DOI · Paper page
  12. Pierce CG , Srinivasan A , Ramasubramanian AK , Lopez-Ribot JL . 2015. From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiol Spectr 3. · DOI
  13. 10.1126/science.aap7999 · DOI · Paper page
  14. 10.1517/17460441.2013.807245 · DOI · Paper page
  15. 2020, Production of Vitamin B2 (Riboflavin) by Microorganisms: An Overview, Front Bioeng Biotechnol, 8, 570828, 10.3389/fbioe.2020.570828 · DOI · Paper page
  16. 2023, Can we microbe-manage our vitamin acquisition for better health?, PLoS Pathog, 19, e1011361, 10.1371/journal.ppat.1011361 · DOI
  17. 10.1016/j.copbio.2012.08.005 · DOI · Paper page
  18. 10.1146/annurev.nutr.20.1.153 · DOI · Paper page
  19. 10.1016/j.sbi.2006.10.003 · DOI
  20. 10.1016/j.addr.2003.07.005 · DOI
  21. 10.1021/jo0703092 · DOI · Paper page
  22. 10.1039/c2np20069d · DOI · Paper page
  23. 10.1042/bst0160416 · DOI
  24. 10.1016/j.abb.2013.02.015 · DOI · Paper page
  25. 2020, Production of riboflavin and related cofactors by biotechnological processes, Microb Cell Fact, 19, 31, 10.1186/s12934-020-01302-7 · DOI · Paper page
  26. 2019, Understanding the riboflavin biosynthesis pathway for the development of antimicrobial agents, Med Res Rev, 39, 1338, 10.1002/med.21576 · DOI
  27. 10.1074/jbc.M505002200 · DOI
  28. Demuyser L , Palmans I , Vandecruys P , Van Dijck P. 2020. Molecular Elucidation of Riboflavin Production and Regulation in Candida albicans, toward a Novel Antifungal Drug Target. mSphere 5. · DOI
  29. 10.1080/21505594.2016.1213937 · DOI · Paper page
  30. 10.1016/j.gene.2004.06.021 · DOI · Paper page
  31. 10.1186/1471-2164-9-579 · DOI
  32. 10.3177/jnsv.54.423 · DOI
  33. 10.1146/annurev.mi.26.100172.002101 · DOI
  34. 1965, Flavin coenzymes, flavinogenesis and reproduction in Ashbya gossypii, J Biochem, 57, 773, 10.1093/oxfordjournals.jbchem.a128144 · DOI
  35. 10.1099/00221287-28-2-283 · DOI
  36. 2020, Expression of yeast homolog of the mammal BCRP gene coding for riboflavin efflux protein activates vitamin B(2) production in the flavinogenic yeast Candida famata, Yeast, 37, 467, 10.1002/yea.3470 · DOI
  37. 10.1093/NAR/GKAB1061 · DOI · Paper page
  38. 10.1093/nar/gky092 · DOI · Paper page
  39. 10.1128/JCM.06112-11 · DOI · Paper page
  40. 10.1101/gr.3672305 · DOI · Paper page
  41. 10.1074/jbc.M409581200 · DOI
  42. 10.1016/S0300-9084(02)01446-3 · DOI
  43. 10.1111/j.1742-4658.2008.06586.x · DOI
  44. 2022, Identification and Functional Analysis of GTP Cyclohydrolase II in Candida glabrata in Response to Nitrosative Stress, Front Microbiol, 13, 825121, 10.3389/fmicb.2022.825121 · DOI
  45. 10.1128/MMBR.00030-10 · DOI · Paper page
  46. 10.17226/6015 · DOI · Paper page
  47. Nguyen N , Quail MMF , Hernday AD. 2017. An Efficient, Rapid, and Recyclable System for CRISPR-Mediated Genome Editing in Candida albicans. mSphere 2. · DOI
  48. 10.1093/genetics/134.3.717 · DOI · Paper page
  49. Demuyser L , Swinnen E , Fiori A , Herrera-Malaver B , Vestrepen K , Van Dijck P. 2017. Mitochondrial Cochaperone Mge1 Is Involved in Regulating Susceptibility to Fluconazole in Saccharomyces cerevisiae and Candida Species. mBio 8. · DOI · Paper page
  50. 10.1002/yea.320110408 · DOI · Paper page
  51. 10.1038/nature02579 · DOI · Paper page
  52. 10.1038/nprot.2007.13 · DOI · Paper page
  53. 10.1080/09687680701342669 · DOI · Paper page

Metadata

Authors
Nysten, J., Peetermans, A., Vaneynde, D., Demuyser, L., & Van Dijck, P.
Affiliations
KU Leuven (BE)
Venue
mBio
Publisher
openRxiv
Published
2024-03-01
Volume
15
Issue
11
Pages
e0250224-e0250224
ISSN
2150-7511 (ISSN-L)
OpenAlex
W4403406750
Cited by
8
References
1
Citations by year
2026: 4 · 2025: 4
FWCI
2.75
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • mBio (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion, cc-by-nc-sa)
  • Chalmers Research (Chalmers University of Technology) (submittedVersion, cc-by-nc-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
Funders
  • Fonds Wetenschappelijk Onderzoek (1S18121N, C14/22/075, 1S19219N, 11PRR24N)
  • KU Leuven (C14/22/075)
  • Onderzoeksraad, KU Leuven (C14/22/075)
  • Vlaamse regering
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
riboflavin biosynthesis, antifungal drug targets, Candida albicans, Candida glabrata, Saccharomyces cerevisiae, riboflavin uptake, fungal virulence, invasive fungal infections, antifungal resistance
MeSH terms
Animals, Antifungal Agents, Candida albicans, Candidiasis, Disease Models, Animal, Fungal Proteins, Riboflavin, Saccharomyces cerevisiae, Virulence, Candida glabrata, Mice, Biosynthetic Pathways

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species. https://app.cochat.ai/papers/10.1101/2024.03.01.582991
The paper
Nysten, J., Peetermans, A., Vaneynde, D., Demuyser, L., & Van Dijck, P. (2024). The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species. mBio. https://doi.org/10.1101/2024.03.01.582991

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.